The diagnostic performance of classical molecular tests used for detecting human papillomavirus

被引:15
作者
Munoz, Marina [1 ,2 ]
Camargo, Milena [1 ,2 ]
Soto-De Leon, Sara C. [1 ,2 ]
Rojas-Villarraga, Adriana [2 ,4 ]
Sanchez, Ricardo [1 ,3 ]
Jaimes, Camilo [2 ]
Perez-Prados, Antonio [5 ]
Patarroyo, Manuel E. [1 ,3 ]
Patarroyo, Manuel A. [1 ,2 ]
机构
[1] Fdn Inst Inmunol Colombia FIDIC, Bogota, Colombia
[2] Univ Rosario, Sch Med & Hlth Sci, Bogota, Colombia
[3] Univ Nacl Colombia, Bogota, Colombia
[4] Ctr Autoimmune Dis Res CREA, Bogota, Colombia
[5] Univ Pabl Navarra, Pamplona, Spain
关键词
Human papillomavirus; Hybrid capture assay 2; Polymerase chain reaction; Screening; Test performance; PCR DETECTION; HPV; DNA; PREVALENCE; WOMEN; RISK; AMPLIFICATION; INFECTION; SEQUENCES; CYTOLOGY;
D O I
10.1016/j.jviromet.2012.05.023
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Cervical samples were evaluated for human papillomavirus (HPV) presence using the hybrid capture-2 (HC2) assay and the polymerase chain reaction (PCR) with three different primer sets (GP5+/6+. MY09/11 and pU1M/2R). PCR results were compared to HC2 and results of all assays were compared to cytological and colposcopy findings. Post-test probability was assessed in individual assays and test combinations. HPV-DNA prevalence was 36.5% with HC2 and 55.2% with PCR. MY09/11 detected HPV-DNA in 38% of samples, GP5+/6+ in 19.1% and pU1M/2R in 16.4%. pU1M/2R and HC2 had the highest concordance (75.31%, k = 0.39 in the whole population; 74.1%, k = 0.5 in women with abnormal cytology). pU1M/2R had the best diagnostic performance, including optimal post-test probabilities and cervical abnormality detection (individually or in a panel of tests). Women positive for pU1M/2R may be at higher risk of disease progression; the assay performance when combined with a Pap smear in cervical cancer screening programs should be evaluated. (C) 2012 Elsevier B.V. All rights reserved.
引用
收藏
页码:32 / 38
页数:7
相关论文
共 41 条
[1]  
[Anonymous], 2002, DIAGNOSTIC TEST CALC
[2]  
[Anonymous], METHODS CORRECTING I
[3]  
[Anonymous], HUM PAP REL CANC COL
[4]  
[Anonymous], MLO MED LAB OBSERVER
[5]  
[Anonymous], ACCIONES PLAN OBLIGA
[6]  
[Anonymous], CLIN MICROBIOLOGY IN
[7]  
Bosch F Xavier, 2003, J Natl Cancer Inst Monogr, P3
[8]   Human papillomavirus in cervical cancer [J].
Bosch F.X. ;
Sanjosé S. .
Current Oncology Reports, 2002, 4 (2) :175-184
[9]  
Carestiato Fernanda N., 2006, Braz J Infect Dis, V10, P331, DOI 10.1590/S1413-86702006000500006
[10]   Environmental co-factors in HPV carcinogenesis [J].
Castellsagué, X ;
Bosch, FX ;
Muñoz, N .
VIRUS RESEARCH, 2002, 89 (02) :191-199